Related content

A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson’s disease – a subjective view

By Horowski R.  

Journal of Neural Transmission, Vol. 114, Iss. 1, 2007-01 ,pp. : 127-134

Springer Publishing Company

Access to resources Recommend Favorite

Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson’s disease

By Shiraishi M.   Kamo T.   Hotta M.   Nemoto S.   Oshima J.   Sugihara H.   Yasaki S.   Kawakami M.   Takahashi Y.   Shimojo S.  

Journal of Neural Transmission, Vol. 111, Iss. 6, 2004-06 ,pp. : 725-732

Springer Publishing Company

Access to resources Recommend Favorite

Dopamine receptor agonists in the therapy of Parkinson’s disease

By Foley P.   Gerlach M.   Double K. L.   Riederer P.  

Journal of Neural Transmission, Vol. 111, Iss. 10-11, 2004-10 ,pp. : 1375-1446

Springer Publishing Company

Access to resources Recommend Favorite

Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro

By Asanuma Masato   Miyazaki Ikuko   Diaz-Corrales Francisco J.   Shimizu Masako   Tanaka Ken-ichi   Ogawa Norio  

Neurological Research, Vol. 27, Iss. 5, 2005-07 ,pp. : 533-539

Maney Publishing

Access to resources Recommend Favorite

Release of [³H]Dopamine from Striatal and Cerebral Cortical Slices from Rats with Thioacetamide-Induced Hepatic Encephalopathy: Different Responses to Stimulation by Potassium Ions and Agonists of Ionotropic Glutamate Receptors

By Borkowska Hanna D.   Oja Simo S.   Saransaari Pirjo   Albrecht Jan  

Neurochemical Research, Vol. 22, Iss. 2, 1997-02 ,pp. : 101-106

Springer Publishing Company

Access to resources Recommend Favorite